



RECEIVED MAY 09 2012

**Cardiac Rhythm Management**  
4100 Hamline Avenue North  
St. Paul, MN 55112-5798  
[www.bostonscientific.com](http://www.bostonscientific.com)

May 7, 2012

Federal Communications Commission  
Office of Engineering and Technology  
7435 Oakland Mills Road  
Columbia, Maryland 21046

Re: Waiver Order DA 11-1427 and Notice of FDA Approval on May 7, 2012 for replacements for Contak Renewal TR product line (ESCCRMN11906)

Federal Communications Commission:

The FCC waiver Order (DA 11-1427) released on August 23, 2011 specifies at paragraph 13 that Boston Scientific shall, in connection with its application for equipment certification for the FCC rules-compliant replacement devices (FCC ID ESCCRMN11906), provide to the Commission the date of final FDA approval of the replacement devices (to align the FCC waiver term with FDA approval).

Final FDA approval for the replacements (the "Ingenio" family of devices, and specifically the "Invive" device) for the Contak Renewal devices was received on May 7, 2012.<sup>1</sup>

Please contact me or attorney Jeff Cook (763.494.2645) with any questions.

Sincerely,

John Rymkiewicz  
Fellow Electrical Engineer  
Boston Scientific CRM  
(651) 582 6869

<sup>1</sup> Under the ordering clause in paragraph 12 of the waiver Order, Boston Scientific may continue to manufacture and market the Contak Renewal TR product lines until twelve months after FDA approval of the replacement devices.